Medications such as semaglutide (Ozempic®, Wegovy®) and tirzepatide (Mounjaro®) have changed the landscape of weight management. For many people, they reduce appetite, quiet “food noise,” and make sustained weight loss possible.
However, the question that often comes up in practice is, how can I maintain my weight loss when I stop taking these medications?
Transitioning off GLP-1 medications requires a structured, long-term approach to prevent “rebound” weight gain, which can occur as appetite and “food noise” return.
The most successful strategies combine a gradual taper of the medication with lifestyle interventions focused on nutrition, exercise, and behavioural shifts.
Firstly – How do GLP-1 receptor agonists work?
GLP-1 receptor agonists mimic the natural hormone glucagon-like peptide-1 (GLP-1), which regulates appetite and blood sugar.
They work by:
- Reducing hunger by acting on the brain’s appetite control centre
- Slowing the rate at which food leaves the stomach, keeping you feeling full for longer
- Helping keep blood sugar levels steady by prompting the pancreas to release insulin when blood sugar levels rise, while reducing glucagon, a hormone that tells the liver to release sugar into the bloodstream
- Supporting metabolic health, including helping the body store and use fat more effectively
These combined effects reduce overall energy intake and improve metabolic markers (Moiz. et al., 2025).
When the medication is withdrawn, these effects gradually diminish. Hunger cues may increase, cravings can return, and the effort required to maintain weight loss often rises. This is why a proactive transition plan is essential.
Tapering Gradually:
Research consistently shows that abruptly stopping GLP-1 medications is associated with weight regain, particularly when sustainable lifestyle behaviours have not yet been established.
A gradual reduction in dosage appears to improve weight stability during the transition period. Research presented at the European Congress on Obesity in 2024 found that people who gradually reduced their dose to zero (over an average of nine weeks) maintained a stable body weight in the first 26 weeks after tapering (Ede., 2025).
Key Health and Lifestyle Strategies:
Weight regain is also slower and less likely to occur when people have healthy lifestyle behaviours in place (West et al., 2026).
Nutrition:
When medication stops, the quality, quantity and timing of food can assist with feeling full and satisfied.
- Prioritise Protein: Aim for approximately 30–40 grams of protein per meal. Protein stimulates satiety hormones (including GLP-1), supports muscle mass, and helps regulate appetite. Include lean meats, fish, eggs, dairy, tofu, legumes, and dairy.
- Increase Fibre Intake: Fibre slows digestion and supports blood glucose stability. Soluble and fermentable fibres (oats, flaxseed, legumes, apples, pears, psyllium, vegetables) form a gel in the stomach and are fermented in the gut to produce short-chain fatty acids, which may stimulate GLP-1 secretion naturally.
- Use Volume Strategically: High-volume, lower-energy foods such as vegetables and salads can help maintain fullness without excessive kilojoule intake.
- Maintain Regular Meals: Skipping meals often leads to rebound hunger later in the day. Structured eating patterns support appetite regulation.
- Practise Mindful Eating: Slowing down, removing distractions, and tuning into hunger and fullness cues helps recalibrate appetite awareness once medication is reduced.
- Anticipate Appetite and Emotional Triggers: As medication is reduced, hunger cues and “food noise” may return. Identify high-risk scenarios in advance – stress, fatigue, social events, travel, or unstructured weekends. Develop a clear plan for these moments (for example, healthy meals before events, review restaurant menus beforehand, alcohol boundaries, or alternative stress-management strategies).
Physical Activity
Research shows that keeping up with exercise after stopping GLP-1 receptor agonists is associated with less weight regain (Jenson et al., 2024). Physical activity also improves insulin sensitivity, increases GLP-1 secretion, and can mitigate muscle loss that often happens during weight loss.
- Strength Training: Include resistance training at least twice a week to maintain or build muscle mass, which helps keep your metabolic rate high. (Binmahfoz et al., 2025)
- Increase Activity Levels: Aim for 150–300 minutes of moderate-intensity aerobic exercise per week. Higher volumes (around 250 minutes per week) are associated with greater long-term weight maintenance success. (Alyafei et al.,2025)
- Prioritise Consistency: Focus on building a routine that you can stick with permanently, rather than intense, temporary workouts.
Behavioural and Lifestyle Foundations
- Sleep: Poor sleep quality or sleep deprivation can increase the hunger hormone ghrelin, reduce GLP-1 levels and delay its peak time after eating, leading to poor appetite regulation. Prioritise 7-9 hours of quality sleep (Figorilli et al., 2025).
- Identify and Plan for High-Risk Situations: Anticipate triggers in advance and develop a plan. This may include structured meal planning, stress-regulation strategies, environmental design (such as removing trigger foods), or building accountability systems. Preparing for predictable high-risk moments reduces reactive decision-making.
- Consistent Monitoring: Track dietary intake, physical activity, sleep or other lifestyle habits to ensure you stay on track. Consider tracking biometrics such as body composition via DEXA scans, and cardiometabolic markers such as blood pressure, lipids (cholesterol and triglycerides), and blood glucose.
Professional ongoing guidance
It is highly recommended to work with healthcare professionals, to create a personalised, safe, and effective plan, and support you to keep forward momentum for long-term weight management.
An interdisciplinary approach – combining medical oversight, dietetics, exercise physiology, and health coaching – provides the structure needed to:
- Create a personalised tapering plan
- Optimise nutrition intake
- Design a strength-focused exercise program
- Monitor metabolic health markers
- Address emotional eating and food triggers
- Support mindset for long-term change
- Build long-term systems for consistency
At Oracle Healthcare, our medical and allied health team works collaboratively to provide support before, during, and after GLP-1 therapy. The goal is durable metabolic health, preserved muscle mass, improved energy, and long-term confidence in your ability to maintain results.
If you are considering transitioning off a GLP-1 medication, or would like support maintaining your progress, we are here to help you build a sustainable, evidence-based plan for the next phase of your health journey.
Written by Shivaun Conn
Senior Dietitian and Health Coach, BSc Nut. HONS APD AN
References:
- Moiz A, Filion K.B, Tsoukas M. A, Yu O. HY, Peters T.M, Eisenberg M.J. Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation. The American Journal of Medicine. 2025; 138(6):934 – 940.
- Ede R. (2025, December 31). Weight Maintenance after GLP-1 RA Withdrawal Exposes Critical Research Gaps. MedCentral.
- West, S., Scragg, J., Aveyard, P., Oke, J. L., Willis, L., Haffner, S. J. P., Knight, H., Wang, D., Morrow, S., Heath, L., Jebb, S. A., & Koutoukidis, D. A. (2026). Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ, 392. https://doi.org/10.1136/bmj-2025-085304
- Jensen S.B.K, Blond M.B, Sandsdal R.M, Olsen L.M, Juhl C.R, Lundgren J.R, Janus C, Stallknecht B.M, Holst J.J, Madsbad S, Torekov S.S. (2024). Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial. EClinicalMedicine, 69, 102475-102475.
- Binmah A, Dighriri A, Gray C, Gray S.R. (2025). Effect of resistance exercise on body composition, muscle strength and cardiometabolic health during dietary weight loss in people living with overweight or obesity: a systematic review and meta-analysis. BMJ Open Sport & Exercise Medicine. 2025;11:e002363. https://doi.org/10.1136/bmjsem-2024-002363
- Alyafei A, Balfour J, Keyes D. (2025). Physical Activity and Weight Loss Maintenance. PubMed; StatPearls Publishing. Available from https://www.ncbi.nlm.nih.gov/books/NBK572051/
